Trials / Active Not Recruiting
Active Not RecruitingNCT05767021
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 172 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirikizumab | Administered IV |
| DRUG | Mirikizumab | Administered Subcutaneously (SC) |
Timeline
- Start date
- 2023-05-17
- Primary completion
- 2024-08-09
- Completion
- 2026-04-01
- First posted
- 2023-03-14
- Last updated
- 2025-10-28
- Results posted
- 2025-09-30
Locations
120 sites across 10 countries: United States, Belgium, Czechia, France, Germany, Hungary, Italy, Poland, Slovakia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05767021. Inclusion in this directory is not an endorsement.